Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$8.77 USD
-0.17 (-1.90%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $8.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYGR 8.77 -0.17(-1.90%)
Will VYGR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
Other News for VYGR
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VYGR Makes Notable Cross Below Critical Moving Average
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics Welcomes New CFO Nathan Jorgensen